Showing 1 - 10 of 114
Entry by rival app stores on the two currently available mobile operating systems is an exciting potential benefit of the European Union's Digital Markets Act (DMA). Apple and Google will need to share the technical specifications of their interfaces with developers and offer them the same...
Persistent link: https://www.econbiz.de/10014497421
Competitiveness is a region's ability to achieve high productivity, attracting businesses, creating jobs and fostering innovation. It stems from efficiently using resources, is driven by competitive markets and is supported by three pillars: competition policy, procompetitive industrial policy...
Persistent link: https://www.econbiz.de/10015077080
Antitrust cases against Amazon in the United States reveal that the e-commerce giant has developed algorithms that mimic price protection contracts called MFNs (from mostfavoured nations, a term borrowed from international trade), despite the company saying publicly that it ended the contracts...
Persistent link: https://www.econbiz.de/10014513686
The European Union's Digital Markets Act (DMA) includes interoperability requirements for messaging services but not for personal social networking platforms. These gatekeeper platforms have seen little increase in competition under the DMA. Interoperability requirements - meaning different...
Persistent link: https://www.econbiz.de/10015406881
Persistent link: https://www.econbiz.de/10001484002
Persistent link: https://www.econbiz.de/10001520135
Persistent link: https://www.econbiz.de/10001832603
Persistent link: https://www.econbiz.de/10003093519
Many industries are characterized by heterogeneous objectives on the part of firm owners. Owners of private firms, in particular, are likely to maximize utility, rather than profits. In this paper, we model and measure motivations of owners in on particular industry, the California wine...
Persistent link: https://www.econbiz.de/10014046857
Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry, however only a few biosimilars have been approved in the US since 2015, thereby largely preserving biologics...
Persistent link: https://www.econbiz.de/10014126235